|Articles|August 4, 2009
OmniComm Systems Acquires EDC Assets of Logos Technologies
Advertisement
8.4.09
Fort Lauderdale, Florida
Fort Lauderdale, Florida
OmniComm Systems (Fort Lauderdale, FL) has acquired the EDC assets of UK-based Logos Technologies, who has U.S. headquarters in Arlington, VA. The acquisition will be led by OmniComm's UK subsidiary OmniComm Ltd. and provide the parent company with EDC products that cover all aspects of the Phase I process, including subject recruitment, clinical workflow management, and laboratory samplemanagement.
"We are pleased to add the Logos products and operations to the OmniComm team,” said Cornelis F. Wit,
OmniComm's President and CEO, in a company press release. "We believe that the addition of the Logos Phase I products is of importance for OmniComm Systems, as it will broaden the scope of our integrated eClinical solutions offering. Only a very small number of EDC companies specialize in the Phase I market, therefore this acquisition represents animportant addition to our overall corporate growth strategy."
OmniComm's President and CEO, in a company press release. "We believe that the addition of the Logos Phase I products is of importance for OmniComm Systems, as it will broaden the scope of our integrated eClinical solutions offering. Only a very small number of EDC companies specialize in the Phase I market, therefore this acquisition represents animportant addition to our overall corporate growth strategy."
OmniComm reports that the new Logos products will complement their TrialMaster software, which is primarily used in later stage clinical trials.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
2
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4